Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro

R. Yerushalmi, J. Nordenberg, E. Beery, O. Uziel, M. Lahav, D. Luria, E. Fenig*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Little is known about the interaction of novel anticancer drugs with other treatment modalities. The aim of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells. Methods: Cell proliferation was determined using the sulphorodamine B cytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis. Results: Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in human MCF-7 breast cancer cells. Conclusion: STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation.

Original languageEnglish
Pages (from-to)126-131
Number of pages6
JournalExperimental Oncology
Issue number2
StatePublished - Jun 2007


  • Apoptosis
  • Cell cycle
  • Cisplatin
  • Gleevec
  • Imatinib mesylate
  • Irradiation
  • Phosphorylated AKT
  • STI-571


Dive into the research topics of 'Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro'. Together they form a unique fingerprint.

Cite this